Potential therapeutic application of EP1 antagonists
EP1 Antagonists | Route | Dose | Species | Experimental Model | Indication | Reference |
---|---|---|---|---|---|---|
ONO-8711 | Intravenous | 1 and 3 mg/kg | Rat | Acetic acid-induced inflammation | Bladder inflammation | Ikeda et al., 2006 |
ONO-8711 | Dietary | 400 or 800 ppm | Rat | PhIP-induced breast cancer | Breast cancer | Kawamori et al., 2001a,b |
ONO-8711 | Dietary | 250, 500, 1000 ppm | Mouse | Azoxymethane-induced aberrant crypt foci, Min mice | Colon cancer | Watanabe et al., 1999 |
ONO-8713 | Oral | 20 mg/kg | Mouse | DNFB contact sensitivity | Contact dermatitis | Nagamachi et al., 2007 |
ONO-8713 | Topical | 50 μg | Mouse | UVB-induced inflammation and tumor formation | Sunburn, skin cancer | Tober et al., 2006 |
ONO-8713 | Dietary | 250, 500 1000 ppm | Mouse | Azoxymethane-induced aberrant crypt foci | Colon cancer | Watanabe et al., 2000 |
ONO-8713 | Intraventricular | 0–1–10 nM | Mouse | NMDA excitotoxicity | Stroke | Ahmad et al., 2006a |
ONO-8713 | Intraperitoneal | 10 mg/kg | Mouse | Cerebral artery occlusion | Stroke | Ahmad et al., 2006a |
ONO-8713 | Intrathecal | 1 or 10 nmol | Mouse | Neurochemical allodynia | Pain | Tsukamoto et al., 2010 |
PF-2907617-02 | Intravenous | 1 mg/kg | Rat | Balloon catheter-induced bladder outlet obstruction | Overactive bladder syndrome | Lee et al., 2007a,b |
SC-51089 | Intraperitoneal | 25 mg/kg | Mice | KMG4 tumor xenografts on SCID mice | Glioma | Matsuo et al., 2004 |
SC-51089 | Intraperitoneal | 10 mg/kg | Rat | Lithium-pilocarpine status epilepticus | Epilepsy | Pekcec et al., 2009 |
SC-51322 | Oral | 10 mg/kg | Rat | Spontaneously hypertensive rat | Hypertension | Guan et al., 2007 |
PhIP, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine; SC-51089, dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-(1-oxo-3-(4-pyridinyl)propyl)hydrazide, monohydrochloride.